Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria by Polman, Chris H et al.
RAPID COMMUNICATION
Diagnostic Criteria for Multiple Sclerosis:
2010 Revisions to the McDonald Criteria
Chris H. Polman, MD, PhD,
1 Stephen C. Reingold, PhD,
2 Brenda Banwell, MD,
3
Michel Clanet, MD,
4 Jeffrey A. Cohen, MD,
5 Massimo Filippi, MD,
6 Kazuo Fujihara, MD,
7
Eva Havrdova, MD, PhD,
8 Michael Hutchinson, MD,
9 Ludwig Kappos, MD,
10
Fred D. Lublin, MD,
11 Xavier Montalban, MD,
12 Paul O’Connor, MD,
13
Magnhild Sandberg-Wollheim, MD, PhD,
14 Alan J. Thompson, MD,
15
Emmanuelle Waubant, MD, PhD,
16 Brian Weinshenker, MD,
17 and Jerry S. Wolinsky, MD
18
New evidence and consensus has led to further revision of the McDonald Criteria for diagnosis of multiple sclerosis.
The use of imaging for demonstration of dissemination of central nervous system lesions in space and time has been
simplified, and in some circumstances dissemination in space and time can be established by a single scan. These
revisions simplify the Criteria, preserve their diagnostic sensitivity and specificity, address their applicability across
populations, and may allow earlier diagnosis and more uniform and widespread use.
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D
iagnostic criteria for multiple sclerosis (MS) include
clinical and paraclinical laboratory assessments
1,2
emphasizing the need to demonstrate dissemination of
lesions in space (DIS) and time (DIT) and to exclude alter-
native diagnoses. Although the diagnosis can be made on
clinical grounds alone, magnetic resonance imaging (MRI)
of the central nervous system (CNS) can support, supple-
ment, or even replace some clinical criteria,
3–9 as most
recently emphasized by the so-called McDonald Criteria of
the International Panel on Diagnosis of MS.
8,9 The McDo-
nald Criteria have resulted in earlier diagnosis of MS with a
high degree of both specificity and sensitivity,
10–13 allowing
for better counseling of patients and earlier treatment.
Since the revision of the McDonald Criteria in
2005, new data and consensus have pointed to the need
for their simplification to improve their comprehension
and utility and for evaluating their appropriateness in pop-
ulations that differ from the largely Western Caucasian
adult populations from which the Criteria were derived.
In May 2010 in Dublin, Ireland, the International Panel
on Diagnosis of MS (the Panel) met for a third time to
examine requirements for demonstrating DIS and DIT
and to focus on application of the McDonald Criteria in
pediatric, Asian, and Latin American populations.
Considerations Related to Revisions to the
McDonald Criteria
The Panel reviewed published research related to the di-
agnosis of MS and to the original and revised McDonald
Criteria, gathered from literature searches of English
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and diagnosis, and from specific recommendations of rele-
v a n tp a p e r sb yP a n e lm e m b e r s .T h eP a n e lc o n c l u d e dt h a t
most recent research supports the utility of the McDonald
Criteria in a typical adult Caucasian population seen in MS
centers, despite only limited research and practical experi-
ence in general neurology practice populations.
In its discussions, the Panel stressed that the McDo-
nald Criteria should only be applied in those patients
who present with a typical clinically isolated syndrome
(CIS) suggestive of MS or symptoms consistent with a
CNS inflammatory demyelinating disease, because the
development and validation of the Criteria have been
limited to patients with such presentations. CIS presenta-
tions can be monofocal or multifocal, and typically
involve the optic nerve, brainstem/cerebellum, spinal
cord, or cerebral hemispheres.
In applying the McDonald Criteria, it remains im-
perative that alternative diagnoses are considered and
excluded. Differential diagnosis in MS has been the sub-
ject of previous data- and consensus-driven recommenda-
tions that point to common and less common alternative
diagnoses for MS and identify clinical and paraclinical
red flags that should signal particular diagnostic cau-
tion.
14,15 In its current review, the Panel focused specifi-
cally on the often-problematic differential diagnosis for
MS of neuromyelitis optica (NMO) and NMO spectrum
disorders. There is increasing evidence of relapsing CNS
demyelinating disease characterized by involvement of
optic nerves (unilateral or bilateral optic neuritis), often
severe myelopathy with MRI evidence of longitudinally
extensive spinal cord lesions, often normal brain MRI (or
with abnormalities atypical for MS), and serum aqua-
porin-4 (AQP4) autoantibodies.
16,17 There was agree-
ment that this phenotype should be separated from typi-
cal MS because of different clinical course, prognosis,
and underlying pathophysiology and poor response to
some available MS disease-modifying therapies.
18 The
Panel recommends that this disorder should be carefully
considered in the differential diagnosis of all patients pre-
senting clinical and MRI features that are strongly sug-
gestive of NMO or NMO spectrum disorder, especially
if (1) myelopathy is associated with MRI-detected spinal
cord lesions longer than 3 spinal segments and primarily
involving the central part of the spinal cord on axial sec-
tions; (2) optic neuritis is bilateral and severe or associ-
ated with a swollen optic nerve or chiasm lesion or an
altitudinal scotoma; and (3) intractable hiccough or nau-
sea/vomiting is present for >2 days with evidence of a
periaqueductal medullary lesion on MRI.
19,20 In patients
with such features, AQP4 serum testing should be used
to help make a differential diagnosis between NMO and
MS to help avoid misdiagnosis and to guide treatment.
Correct interpretation of symptoms and signs is a
fundamental prerequisite for diagnosis.
21 The Panel con-
sidered again what constitutes an attack (relapse, exacer-
bation) and defined this as patient-reported symptoms or
objectively observed signs typical of an acute inflamma-
tory demyelinating event in the CNS, current or histori-
cal, with duration of at least 24 hours, in the absence of
fever or infection. Although a new attack should be
documented by contemporaneous neurological examina-
tion, in the appropriate context, some historical events
with symptoms and evolution characteristic for MS, but
for which no objective neurological findings are docu-
mented, can provide reasonable evidence of a prior
demyelinating event. Reports of paroxysmal symptoms
(historical or current) should, however, consist of multi-
ple episodes occurring over not less than 24 hours. There
was consensus among the Panel members that before a
definite diagnosis of MS can be made, at least 1 attack
must be corroborated by findings on neurological exami-
nation, visual evoked potential (VEP) response in
patients reporting prior visual disturbance, or MRI con-
sistent with demyelination in the area of the CNS impli-
cated in the historical report of neurological symptoms.
The Panel concluded that the underlying concepts
of the original (2001) and revised (2005) McDonald Cri-
teria
8,9 are still valid, including the possibility of estab-
lishing a diagnosis of MS based on objective demonstra-
tion of dissemination of lesions in both space and time
on clinical grounds alone or by careful and standardized
integration of clinical and MRI findings. However, the
Panel now recommends key changes in the McDonald
Criteria related to the use and interpretation of imaging
criteria for DIS and DIT as articulated by the recently
published work from the MAGNIMS research group.
22–24
Such changes are likely to further increase diagnostic sensi-
tivity without compromising specificity, while simplifying
the requirements for demonstration of both DIS and
DIT, with fewer required MRI examinations. The Panel
also makes specific recommendations for application of
the McDonald Criteria in pediatric and in Asian and
Latin American populations.
Recommended Modifications to the McDonald
Criteria: The 2010 Revisions
MAGNETIC RESONANCE IMAGING CRITERIA FOR
DIS. In past versions of the McDonald Criteria, DIS
demonstrated by MRI was based on the Barkhof/Tintore ´
criteria.
4,6 Despite having good sensitivity and specificity,
these criteria have been difficult to apply consistently by
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25,26 The European MAGNIMS
multicenter collaborative research network, which studies
MRI in MS, compared the Barkhof/Tintore ´ criteria for
DIS
4,6 with simplified criteria developed by Swanton and
colleagues.
22,27 In the MAGNIMS work, DIS can be
demonstrated with at least 1 T2 lesion in at least 2 of 4
locations considered characteristic for MS and as speci-
fied in the original McDonald Criteria (juxtacortical,
periventricular, infratentorial, and spinal cord), with
lesions within the symptomatic region excluded in
patients with brainstem or spinal cord syndromes. In 282
CIS patients, the Swanton-based DIS criteria were shown
to be simpler and slightly more sensitive than the origi-
nal McDonald Criteria for DIS, without compromising
specificity and accuracy.
22 The Panel accepted these
MAGNIMS DIS Criteria, which can simplify the diag-
nostic process for MS while preserving specificity and
improving sensitivity (Table 1).
MAGNETIC RESONANCE IMAGING CRITERIA FOR
DIT. The 2005 revision of the McDonald Criteria sim-
plified the MRI evidence required for DIT, basing it on
the appearance of a new T2 lesion on a scan compared
to a reference or baseline scan performed at least 30 days
after the onset of the initial clinical event.
9 In clinical
practice, however, there is reason not to postpone a first
MRI until after 30 days of clinical onset, which would
result in an extra MRI scan to confirm a diagnosis. Aban-
doning the requirement for an extra reference MRI after
30 days does not compromise specificity,
28 and therefore
the Panel, in its current revision of the McDonald Crite-
ria, allows a new T2 lesion to establish DIT irrespective of
the timing of the baseline MRI.
More recently, the MAGNIMS group confirmed
earlier studies
29,30 by showing that, in patients with typi-
cal CIS, a single brain MRI study that demonstrates DIS
and both asymptomatic gadolinium-enhancing and non-
enhancing lesions is highly specific for predicting early
development of clinically definite MS (CDMS) and reli-
ably substitutes for prior imaging criteria for DIT.
23,24
After review of these data, the Panel accepted that the
presence of both gadolinium-enhancing and nonenhancing
lesions on the baseline MRI can substitute for a follow-up
scan to confirm DIT (Table 2), as long as it can be reli-
ably determined that the gadolinium-enhancing lesion is
not due to non-MS pathology.
By using the recommended simplified MAGNIMS
criteria to demonstrate DIS
22 and allowing DIT to be
demonstrated by a scan containing both enhancing and
nonenhancing lesions in regions of the CNS typical for
MS,
23 a diagnosis of MS can be made in some CIS
patients based on a single MRI.
24 The Panel felt this is
justified because it simplifies the diagnostic process with-
out reducing accuracy. However, a new clinical event or
serial imaging to show a new enhancing or T2 lesion will
still be required to establish DIT in those patients who
do not have both gadolinium-enhancing and nonenhanc-
ing lesions on their baseline MRI.
THE VALUE OF CEREBROSPINAL FLUID FINDINGS IN
DIAGNOSIS. The Panel reaffirmed that positive cere-
brospinal fluid (CSF) findings (elevated immunoglobulin
G [IgG] index or 2 or more oligoclonal bands) can be
important to support the inflammatory demyelinating
nature of the underlying condition, to evaluate alternative
diagnoses, and to predict CDMS.
15,31 In the 2001 and
2005 McDonald Criteria, a positive CSF finding could
be used to reduce the MRI requirements for reaching
DIS criteria (requiring only 2 or more MRI-detected
lesions consistent with MS if the CSF was positive).
8,9
However, when applying the simplified MAGNIMS
TABLE 1: 2010 McDonald MRI Criteria for
Demonstration of DIS
DIS Can Be Demonstrated by  1 T2 Lesion
a in at
Least 2 of 4 Areas of the CNS:
Periventricular
Juxtacortical
Infratentorial
Spinal cord
b
Based on Swanton et al 2006, 2007.
22,27
aGadolinium enhancement of lesions is not required for
DIS.
bIf a subject has a brainstem or spinal cord syndrome, the
symptomatic lesions are excluded from the Criteria and do
not contribute to lesion count.
MRI ¼ magnetic resonance imaging; DIS ¼ lesion dissemi-
nation in space; CNS ¼ central nervous system.
TABLE 2: 2010 McDonald MRI Criteria for
Demonstration of DIT
DIT Can Be Demonstrated by:
1. A new T2 and/or gadolinium-enhancing lesion(s)
on follow-up MRI, with reference to a baseline scan,
irrespective of the timing of the baseline MRI
2. Simultaneous presence of asymptomatic
gadolinium-enhancing and nonenhancing
lesions at any time
Based on Montalban et al 2010.
24
MRI ¼ magnetic resonance imaging; DIT ¼ lesion dissemi-
nation in time.
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24 the Panel believes
that even further liberalizing MRI requirements in CSF-
positive patients is not appropriate, as CSF status was not
evaluated for its contribution to the MAGNIMS criteria
for DIS and DIT.
22,24 Prospective studies using widely
available standardized techniques and the most sensitive
methods of detection of oligoclonal bands in the CSF to-
gether with the new imaging requirements are needed to
confirm the additional diagnostic value of CSF.
32,33
MAKING A DIAGNOSIS OF PRIMARY PROGRESSIVE
MULTIPLE SCLEROSIS. In 2005, the Panel recom-
mended revising the McDonald Criteria for diagnosis of
primary progressive multiple sclerosis (PPMS) to require,
in addition to 1 year of disease progression, 2 of the fol-
lowing 3 findings: positive brain MRI (9 T2 lesions or 4
or more T2 lesions with positive VEP); positive spinal
cord MRI (2 focal T2 lesions); or positive CSF. These
criteria reflected the special role of both CSF examina-
tion and spinal cord MRI in PPMS, have been found to
be practical and are generally well accepted by the neuro-
logical community,
34 and have been used as inclusion cri-
teria for PPMS clinical trials.
35 To harmonize MRI criteria
within the diagnostic criteria for all forms of MS, while
recognizing the special diagnostic needs for PPMS, the
Panel recommends that the McDonald Criteria require-
ment of fulfilling 2 of 3 MRI or CSF findings be main-
tained for PPMS, with replacement of the previous brain
imaging criterion with the new MAGNIMS brain imaging
criterion for DIS (2 of 3 of the following:  1 T2 lesions
in at least 1 area characteristic for MS [periventricular, jux-
tacortical, or infratentorial];  2 T2 lesions in the cord; or
positive CSF [isoelectric focusing evidence of oligoclonal
bands and/or elevated IgG index]) (Table 3). This consen-
sus-based recommendation is justified by comparing diag-
nostic criteria for PPMS
36 and by a subsequent reanalysis
of these data (X. Montalban, personal communication).
Use of MAGNIMS-based imaging criteria for PPMS with
or without associated CSF evaluation should be supported
by additional data further documenting the sensitivity and
specificity of the criteria in this population.
APPLICABILITY OF THE MCDONALD CRITERIA IN
PEDIATRIC, ASIAN, AND LATIN AMERICAN POPULA-
TIONS. The McDonald Criteria were developed with
data gathered largely from adult Caucasian European and
North American populations, and their applicability has
been questioned for other populations, particularly pedi-
atric cases,
37,38 Asians,
39,40 and Latin Americans.
41
Pediatric MS
Over 95% of pediatric MS patients have an initial relaps-
ing–remitting disease course, whereas PPMS is excep-
tional in children and should prompt detailed considera-
tion of alternative diagnoses.
42–45 About 80% of pediatric
cases, and nearly all adolescent onset cases, present with
attacks typical for adult CIS, with a similar or greater total
T2 lesion burden.
46–48 In children younger than 11 years,
lesions are larger and more ill-defined than in teenagers.
49
Imaging criteria for demonstrating DIS in pediatric MS
show high sensitivity and/or specificity.
38,50,51
The Panel’s consensus was that the proposed MAG-
NIMS-based MRI revisions for DIS will also serve well
for most pediatric MS patients, especially those with acute
demyelination presenting as CIS, because most pediatric
patients will have >2 lesions and are very likely to have
lesions in 2 of the 4 specified CNS locations (periventricu-
lar, brainstem-infratentorial, juxtacortical, or spinal cord).
The frequency of spinal cord lesions in pediatric MS
patients is currently unreported, but the appearance of
cord lesions in pediatric MS patients with spinal cord
symptoms appears generally similar to that of adults.
52
However, approximately 15 to 20% of pediatric
MS patients, most aged <11 years, present with ence-
phalopathy and multifocal neurological deficits difficult
to distinguish from acute disseminated encephalomyelitis
(ADEM).
43,50 Current operational international consen-
sus criteria for MS diagnosis in children with an ADEM-
like first attack require confirmation by 2 or more non-
ADEM like attacks, or 1 non-ADEM attack followed by
accrual of clinically silent lesions.
53 Although children
with an ADEM-like first MS attack are more likely
than children with monophasic ADEM to have 1 or
more non-enhancing T1 hypointense lesions, 2 or more
TABLE 3: 2010 McDonald Criteria for Diagnosis of
MS in Disease with Progression from Onset
PPMS May Be Diagnosed in Subjects With:
1. One year of disease progression (retrospectively
or prospectively determined)
2. Plus 2 of the 3 following criteria
a:
A. Evidence for DIS in the brain based on  1T 2
b
lesions in at least 1 area characteristic for MS
(periventricular, juxtacortical, or infratentorial)
B. Evidence for DIS in the spinal cord based
on  2T 2
b lesions in the cord
C. Positive CSF (isoelectric focusing evidence of
oligoclonal bands and/or elevated IgG index)
aIf a subject has a brainstem or spinal cord syndrome, all
symptomatic lesions are excluded from the Criteria.
bGadolinium enhancement of lesions is not required.
MS ¼ multiple sclerosis; PPMS ¼ primary progressive MS;
DIS ¼ lesion dissemination in space; CSF ¼ cerebrospinal
fluid; IgG ¼ immunoglobulin G.
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pattern,
54 these features are not absolutely discriminatory.
Furthermore, MRI scans of children with monophasic
ADEM typically demonstrate multiple variably enhancing
lesions (often >2) typically located in the juxtacortical
white matter, infratentorial space, and spinal cord. Thus,
application of the revised MAGNIMS-based criteria for
DIS and DIT on initial MRI would be inappropriate for
such patients, and serial clinical and MRI observations are
required to confirm a diagnosis of MS. In this young age
group, there can be marked lesion resolution following an
initial attack
49 prior to emergence over time of new lesions
and attacks leading to a diagnosis of MS.
MS in Asian and Latin American Populations
Among Asian patients with CNS inflammatory demyeli-
nating disease, a phenotype characterized by NMO, lon-
gitudinally extensive spinal cord lesions, and positive
AQP4 autoantibody seropositivity
19 has been relatively
more common than in Western populations.
55–57 The
Panel solicited input on use of the McDonald Criteria in
Asia and Latin America, where there is evidence of a sim-
ilar phenotype distinction.
41 Although the McDonald
Criteria are widely used in these parts of the world, there
is some uncertainty, especially in Asia, about whether MS
and NMO are distinct and if so, how they should be dis-
tinguished.
39 As currently applied, the term opticospinal
MS appears to be an admixture of conventional MS and
NMO. Confusion has arisen (1) because of the recognition
that most cases of NMO are relapsing; (2) because AQP4
autoantibody testing has facilitated the diagnosis of NMO
and permitted inclusion of individuals with symptomatic
brain lesions who would previously have been excluded;
and (3) because of the recognition that selective involve-
ment of optic nerve and spinal cord alone does not differ-
entiate NMO from MS.
58 It is insufficient to make a diag-
nosis of NMO in the absence of the required specificity
criteria of the revised Wingerchuk Criteria for ‘‘definite’’
NMO, which recommend presence of optic neuritis, acute
myelitis, and at least 2 of 3 supportive paraclinical assess-
ments (a contiguous spinal cord lesion at least 3 segments
in length, brain MRI at onset that is nondiagnostic for
MS, or NMO-IgG seropositivity).
59 These criteria are suc-
cessful in most instances to distinguish NMO from MS in
patients with optic neuritis and myelitis, but the spectrum
of NMO includes recurrent myelitis and optic neuritis,
NMO syndromes with symptomatic brain lesions at pre-
sentation, and NMO associated with systemic autoimmune
diseases.
60 Failure to make the correct diagnosis in patients
with NMO may impact treatment.
20
The Panel recommends testing for AQP4 autoanti-
bodies with validated assays in patients who are suspected
of having NMO or NMO spectrum disorders, especially in
patients with Asian or Latin American genetic background
because of the higher prevalence of the disease in these
populations. Such testing may be less important in those
subjects presenting with conventional Western type MS.
Although not all patients with an NMO-like presentation
will be AQP4 antibody positive, the majority are, whereas
those with MS are more likely to be AQP4 antibody nega-
tive.
16,56,61 C u r r e n te v i d e n c es u g g e s t st h a to n c eN M Oa n d
NMO spectrum disorders have been excluded, Western
type MS in Asia or Latin America is not fundamentally dif-
ferent from typical MS in the Caucasian population, and
that the MAGNIMS MRI criteria would apply for such
patients, although confirmatory studies should be done.
The McDonald Criteria: 2010 Revisions
APPLICATION OF THE CRITERIA. The Panel recom-
mends revisions to the McDonald Criteria for diagnosis of
MS (Table 4) focusing specifically on requirements to dem-
onstrate DIS, DIT, and on diagnosis of PPMS. These 2010
revisions to the McDonald Criteria are likely to be applica-
ble in pediatric, Asian, and Latin American populations
once careful evaluation for other potential explanations for
the clinical presentation is made. The predictive validity of
DIS and DIT based on a single first scan in children with
CIS needs to be confirmed in prospective studies. The
McDonald Criteria have not yet been validated in Asian
and Latin American populations, and studies need to be
done to confirm the sensitivity and specificity of the Criteria
in such patients. Care must be taken to exclude NMO as a
differential diagnosis, which can be confounded by the
imperfect sensitivity of AQP-4 autoantibody assays, the pres-
ence of brain lesions in NMO, and the difficulty of detect-
ing long spinal cord lesions in immunosuppressed patients.
Future Directions
POTENTIAL ADDED VALUE OF BIOMARKERS. Al-
though increased IgG index or the presence of oligoclonal
bands in the CSF support an MS diagnosis, and AQP4
antibody assays can help in the differential diagnosis pro-
cess, there are still no specific biomarkers to confirm the di-
agnosis. Several blood and CSF biomarkers may be promis-
ing,
62–65 and high-resolution spectral domain optical
coherence tomography might be as good as VEP in assess-
ing visual involvement.
66 The diagnostic utility of such
markers needs to be validated and tested prospectively.
REFINEMENTS IN IMAGING CRITERIA. The McDo-
nald Criteria were based on detection of lesions generally
using 1.5T magnet strength in noncortical regions of the
brain and spinal cord. However, a large proportion of
296 Volume 69, No. 2
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Clinical Presentation Additional Data Needed for MS Diagnosis
 2 attacks
a; objective clinical
evidence of  2 lesions or objective
clinical evidence of 1 lesion with
reasonable historical
evidence of a prior attack
b
None
c
 2 attacks
a; objective clinical
evidence of 1 lesion
Dissemination in space, demonstrated by:
 1 T2 lesion in at least 2 of 4 MS-typical regions of the CNS
(periventricular, juxtacortical, infratentorial, or spinal cord)
d;o r
Await a further clinical attack
a implicating a different CNS site
1 attack
a; objective clinical
evidence of  2 lesions
Dissemination in time, demonstrated by:
Simultaneous presence of asymptomatic gadolinium-enhancing
and nonenhancing lesions at any time; or
A new T2 and/or gadolinium-enhancing lesion(s) on follow-up
MRI, irrespective of its timing with reference to a baseline scan; or
Await a second clinical attack
a
1 attack
a; objective clinical
evidence of 1 lesion
(clinically isolated syndrome)
Dissemination in space and time, demonstrated by:
For DIS:
 1 T2 lesion in at least 2 of 4 MS-typical regions of the CNS
(periventricular, juxtacortical, infratentorial, or spinal cord)
d;o r
Await a second clinical attack
a implicating a different CNS site; and
For DIT:
Simultaneous presence of asymptomatic gadolinium-enhancing
and nonenhancing lesions at any time; or
A new T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI,
irrespective of its timing with reference to a baseline scan; or
Await a second clinical attack
a
Insidious neurological progression
suggestive of MS (PPMS)
1 year of disease progression (retrospectively or prospectively
determined) plus 2 of 3 of the following criteria
d:
1. Evidence for DIS in the brain based on  1 T2 lesions in the
MS-characteristic (periventricular, juxtacortical, or infratentorial) regions
2. Evidence for DIS in the spinal cord based on  2T 2
lesions in the cord
3. Positive CSF (isoelectric focusing evidence of oligoclonal bands
and/or elevated IgG index)
If the Criteria are fulfilled and there is no better explanation for the clinical presentation, the diagnosis is ‘‘MS’’; if suspicious, but
the Criteria are not completely met, the diagnosis is ‘‘possible MS’’; if another diagnosis arises during the evaluation that better
explains the clinical presentation, then the diagnosis is ‘‘not MS.’’
aAn attack (relapse; exacerbation) is defined as patient-reported or objectively observed events typical of an acute inflammatory
demyelinating event in the CNS, current or historical, with duration of at least 24 hours, in the absence of fever or infection. It
should be documented by contemporaneous neurological examination, but some historical events with symptoms and evolution
characteristic for MS, but for which no objective neurological findings are documented, can provide reasonable evidence of a prior
demyelinating event. Reports of paroxysmal symptoms (historical or current) should, however, consist of multiple episodes occur-
ring over not less than 24 hours. Before a definite diagnosis of MS can be made, at least 1 attack must be corroborated by findings
on neurological examination, visual evoked potential response in patients reporting prior visual disturbance, or MRI consistent
with demyelination in the area of the CNS implicated in the historical report of neurological symptoms.
bClinical diagnosis based on objective clinical findings for 2 attacks is most secure. Reasonable historical evidence for 1 past attack,
in the absence of documented objective neurological findings, can include historical events with symptoms and evolution character-
istics for a prior inflammatory demyelinating event; at least 1 attack, however, must be supported by objective findings.
cNo additional tests are required. However, it is desirable that any diagnosis of MS be made with access to imaging based on these
Criteria. If imaging or other tests (for instance, CSF) are undertaken and are negative, extreme caution needs to be taken before
making a diagnosis of MS, and alternative diagnoses must be considered. There must be no better explanation for the clinical pre-
sentation, and objective evidence must be present to support a diagnosis of MS.
dGadolinium-enhancing lesions are not required; symptomatic lesions are excluded from consideration in subjects with brainstem
or spinal cord syndromes.
MS ¼ multiple sclerosis; CNS ¼ central nervous system; MRI ¼ magnetic resonance imaging; DIS ¼ dissemination in space; DIT ¼
dissemination in time; PPMS ¼ primary progressive multiple sclerosis; CSF ¼ cerebrospinal fluid; IgG ¼ immunoglobulin G.
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67,68 and can be detected
using double inversion recovery imaging.
69–74 The pres-
ence of at least 1 intracortical lesion in subjects with CIS
may help identify subjects at high risk for developing
CDMS.
75 Magnet strengths >1.5T with tailored acquisi-
tion protocols
76–79 may also enhance diagnosis, with
improvements in image resolution, signal-to-noise ratio,
and chemical shift. Scans at 7.0T showed lesions in the
white and gray matter with enhanced in vivo detection
of pathological hallmarks of MS lesions.
80–83 Finally,
MRI techniques such as magnetic transfer imaging allow
the detection of damage outside focal lesions (for
instance, in normal-appearing brain tissues) not present
in conditions such as ADEM and NMO.
15,84,85 The
utility of these scanning technologies for MS diagnosis in
patients with CIS remains a matter for future research
and validation.
Many individuals with high lesion loads may have
had a protracted subclinical disease course prior to their
first clinical event. As a consequence, occasional individu-
als investigated by MRI for indications unrelated to MS
have incidental findings of brain lesions with appearance
and topography consistent with MS. Detection of this
presymptomatic phase, or radiologically isolated syn-
drome, is increasingly common. Some of these individu-
als followed clinically and by serial imaging will develop
DIT by MRI, and some have clinical disease-defining
events after several years.
86–89 However, in the absence of
supportive research findings, the Panel concluded that a
firm diagnosis of MS based on incidental findings on
MRI alone, even with additional supportive findings on
evoked potentials or typical CSF findings in the absence
of MS-relevant clinical symptoms, is problematic. A
future definite diagnosis of MS, however, cannot be
excluded and may be likely, depending on the evolution
of neurologic symptoms and signs.
Conclusions
The 2010 revisions to the McDonald Criteria will in
some instances allow a more rapid diagnosis of MS, with
equivalent or improved specificity and/or sensitivity com-
pared with past Criteria and will in many instances clar-
ify and simplify the diagnostic process with fewer
required MRI examinations. A proportion of patients with
nonspecific symptoms (eg, fatigue, weakness, or dizziness)
and nonspecific MRI findings are referred to secondary
and tertiary MS centers in the developed world for a sec-
ond opinion and do not in fact have MS.
90 These revised
McDonald Criteria for MS diagnosis should therefore be
applied only when patients have experienced a typical CIS
(or progressive paraparesis/cerebellar/cognitive syndrome in
the case of suspected PPMS).
The Panel acknowledges that using these refined
diagnostic criteria may change some of the outcomes of
patients in natural history studies and clinical trials,
when original expectations for outcomes may be based
on subjects whose diagnosis was made using past, some-
what different criteria.
91 Most of the currently recom-
mended revisions are based upon new data generated
since the 2005 revisions. However, there remains a need
for further testing in prospective and retrospective data-
sets of many of these criteria, especially in populations of
patients typical of those seen in general neurology prac-
tices, both to further assess their value and utility and to
provide suggestions for further refinements in the future.
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